M&A / Deals Roche sticks with C4T, adding up to $1B for molecular glue partnership pharminent April 9, 2026
M&A / Deals Novartis-backed Sidewinder collects $137M series B to strike at difficult-to-treat tumors pharminent April 9, 2026
Policy / Pricing The FTC Blows Up Express Scripts’ PBM Model–and Launches the Net Pricing Drug Channel (rerun) pharminent April 9, 2026
Regulatory FDA seeks permanent future for rare pediatric priority review vouchers pharminent April 9, 2026
M&A / Deals With 3 quick buyouts, Gilead leans into its latest transformation pharminent April 8, 2026
M&A / Deals Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities pharminent April 8, 2026
Market Access Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment Update pharminent April 8, 2026
M&A / Deals Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic pharminent April 8, 2026
Pipeline Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway pharminent April 8, 2026
M&A / Deals Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data pharminent April 8, 2026
Policy / Pricing List Price Reductions Will Deflate the Gross-to-Net Bubble-and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun) pharminent April 8, 2026
M&A / Deals RoosterBio and MineBio team up to expand MSC solutions access in China pharminent April 8, 2026
M&A / Deals Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis pharminent April 7, 2026
M&A / Deals Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis pharminent April 7, 2026
Other 219: An Interview With Dr. Natalie Truba on the Psychological Aspects of Gene Therapy pharminent April 7, 2026
Policy / Pricing AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies pharminent April 7, 2026
Clinical Data Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease pharminent April 7, 2026
Regulatory FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes pharminent April 7, 2026
Clinical Data CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment pharminent April 7, 2026
Manufacturing In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe pharminent April 7, 2026
Clinical Data Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off pharminent April 7, 2026
Clinical Data Sanofi immune drug hopeful posts mixed results in mid-stage tests pharminent April 7, 2026
Clinical Data Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3 pharminent April 7, 2026
